TriangleHEALTH PROFESSIONAL · SOURCE READING
Treatment Options Under Clinical Evaluation for Malignant Extragonadal Extracranial GCTs
Source: Childhood Extracranial Germ Cell Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: November 5, 2024 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
Context: Treatment of Malignant Extragonadal Extracranial GCTs in Children
Information about National Cancer Institute (NCI)–supported clinical trials can be found on the NCI website. For information about clinical trials sponsored by other organizations, see the ClinicalTrials.gov website.
Source links and citations
The following is an example of a national and/or institutional clinical trial that is currently being conducted:
AGCT1531 (NCT03067181) (Active Surveillance, Bleomycin, Carboplatin, Etoposide, or Cisplatin in Treating Pediatric and Adult Patients with GCTs): The aim of this trial is to reduce toxicity and maintain efficacy of treatment for patients with standard-risk GCTs. Patients with stage I malignant GCTs (low risk, age 0–50 years) will be treated with surgery and observation. Patients with intermediate-risk GCTs will be randomly assigned to receive cisplatin or carboplatin and bleomycin and etoposide. Children younger than 11 years will receive bleomycin with each cycle, and those aged 11 years and older will receive weekly bleomycin. Patients with pure seminoma or dysgerminoma are excluded from the trial.
Source links and citations
Studies cited in this source section
Source citation is not a determination that a study applies to you.
Preserved source evidence · Not medical advice